Albireo Pharma Inc (ALBO)
Market Closed
2 Mar, 20:00
NASDAQ (CM) NASDAQ (CM) Primary $
44. 15
0
0%
$
915.89M Market Cap
- P/E Ratio
- Div Yield
1.24M Volume
- Eps
$ 44.15
Previous Close Investors:
Want to track ALBO and more in your Portfolio? 🎯
Sign up for Marketlog, a portfolio tracker that will exceed your expectations!
Summary
ALBO closed Thursday higher at $44.15, an increase of 0% from Wednesday's close, completing a monthly increase of 0% or $44.15. Over the past 12 months, ALBO stock gained 0%.
ALBO is not paying dividends to its shareholders.
Albireo Pharma Inc has completed 2 stock splits, with the recent split occurring on Nov 04, 2016.
The company's stock is traded on one exchange.
Albireo Pharma Inc Investors
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
| NA Nizar Araji National Bank Of Canada /FI/ | 191 | $4,448.39 | $8,432.65 | $3,984.26 | 89.57% |
Albireo Pharma Inc (ALBO) FAQ
What is the stock price today?
The current price is $44.15.
On which exchange is it traded?
Albireo Pharma Inc is listed on NASDAQ (CM).
What is its stock symbol?
The ticker symbol is ALBO.
Does it pay dividends? What is the current yield?
It does not pay dividends to its shareholders.
What is its market cap?
As of today, the market cap is 915.89M.
Has Albireo Pharma Inc ever had a stock split?
Albireo Pharma Inc had 2 splits and the recent split was on Nov 04, 2016.
Albireo Pharma Inc Profile
| Biotechnology Industry | Healthcare Sector | Ronald H. W. Cooper CEO | NASDAQ (CM) Exchange | 01345P106 CUSIP |
| US Country | 130 Employees | - Last Dividend | 4 Nov 2016 Last Split | - IPO Date |
Overview
Albireo Pharma, Inc. is a biopharmaceutical company focused on the research, development, and commercialization of innovative treatments that modify bile acids. With a strong commitment to addressing rare liver diseases, particularly in children, the company is dedicated to improving the lives of patients suffering from various liver and digestive conditions. Its headquarters are situated in Boston, Massachusetts, positioning it at the heart of the biopharmaceutical industry.
Products and Services
- Bylvay: Bylvay is a treatment specifically approved for progressive familial intrahepatic cholestasis (PFIC), a rare liver disease affecting children. The product is currently undergoing advanced (Phase III) clinical trials for additional pediatric indications including biliary atresia and Alagille syndrome, both of which are serious and uncommon disorders.
- Elobixibat: This medication is prescribed for managing persistent constipation and other functional gastrointestinal issues. Albireo Pharma holds a licensing agreement with EA Pharma Co., Ltd. for the development and market rollout of Elobixibat, ensuring its availability to patients in need.
- A3907: Currently in early-stage (Phase I) clinical investigation, A3907 is designed to address adult liver diseases. This product aims to provide new therapeutic options for adults experiencing serious liver conditions.
- A2342: A preclinical candidate, A2342 is being developed to target adult viral and liver conditions. This promising investigational treatment represents Albireo’s ongoing commitment to advancing innovative solutions in the field of liver health.
Contact Information
Address: 10 Post Office Square
Phone: 857 254 5555
Website: https://www.albireopharma.com
